Capital Asset Advisory Services’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Capital Asset Advisory Services’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,561	Closed	-$383K	–	718
2021 Q2	$383K	Sell	5,561 -1,423	-20%	-$109K	0.04%	311
2021 Q1	$538K	Buy	6,984 +1,167	+20%	+$108K	0.08%	235
2020 Q4	$576K	Buy	5,817 +3,474	+148%	+$425K	0.1%	176
2020 Q3	$332K	Buy	2,343 +349	+18%	+$58.2K	0.07%	217
2020 Q2	$370K	Buy	1,994 +245	+14%	+$50.7K	0.08%	220
2020 Q1	$388K	Buy	1,749 +237	+16%	+$51K	0.1%	168
2019 Q4	$388K	Buy	+1,512	New	+$280K	0.09%	218

Other funds holding LKFT

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Capital Asset Advisory Services's LKFT Position: Q3 2021 in Review

Capital Asset Advisory Services sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2021, closing a stake of 5,561 shares — an estimated $383K sold.

Capital Asset Advisory Services first reported a position in LKFT in Q4 2019 and held it in 7 quarters. The position peaked at $576K in Q4 2020. 81 funds tracked by Wall St. Rank hold LKFT as of Q3 2021.

Capital Asset Advisory Services reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2021 after selling out during the quarter.
Capital Asset Advisory Services sold 5,561 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2021, an estimated $383K.
Capital Asset Advisory Services first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2019 and held it in 7 quarters.
Capital Asset Advisory Services's Lakefront Biotherapeutics American Depositary Shares position peaked at $576K in Q4 2020.
81 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2021.

Based on Capital Asset Advisory Services's 13F filing for Q3 2021, filed 14 Oct 2021.